Allon Appoints Dr. Michael Gold Chief Medical Officer
Gold will be responsible for all clinical development programs and medical affairs at Allon. His primary focus will be the global pivotal trial underway with Allon’s davunetide program. This trial is evaluating davunetide as a therapy for progressive supranuclear palsy (PSP), a rapidly progressing and fatal degenerative brain disease. Allon is currently enrolling patients in this trial in North America, Europe, and Australia, following the protocol approved under the Special Protocol Assessment (SPA) issued by United States Food and Drug Administration (FDA).
Gold received his M.D. from the University of Miami Medical School and is board certified in neurology and psychiatry. He has been an Assistant Professor of Neurology at the University of South Florida (USF) Medical School and Director of the USF Memory Disorders Clinic. In 1998, Gold joined Bristol-Myers Squibb in pharmacology and experimental medicine. He subsequently moved to Johnson & Johnson (J&J) in 2001 where he made significant contributions to the FDA approval of several compounds as well as being responsible for strategic development within the company’s analgesia and neurodegeneration franchises.
From J&J, Gold moved to GSK in 2005 where he held various leadership responsibilities in neurological clinical development from Phase 2 clinical trials through regulatory approval, including supporting global registration and commercialization of new products.
Gold will take up his new responsibilities at Allon effective March 7, 2011.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.